https://doi.org/10.4081/monaldi.2026.4166
Eosinophilic myocarditis in platelet-derived growth factor receptor α-rearranged myeloid neoplasm with central nervous system involvement: a case report
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 12 October 2026
Published: 27 October 2026
Eosinophilic myocarditis is a rare inflammatory condition caused by eosinophilic infiltration of the myocardium, often associated with systemic or hematologic disorders.
We report a 31-year-old man with a newly diagnosed platelet-derived growth factor receptor α-rearranged myeloid neoplasm who presented with acute chest pain and elevated cardiac biomarkers. Echocardiography showed Loeffler-type apical involvement, coronary computed tomography angiography excluded obstructive coronary disease, and cardiac magnetic resonance (CMR) demonstrated acute non-ischemic inflammatory myocardial injury. During hospitalization, neurological symptoms revealed central nervous system involvement by the underlying myeloid neoplasm. Corticosteroids and targeted hematologic treatment resulted in marked clinical and radiologic improvement.
On long-term follow-up, CMR showed normal cardiac function with complete resolution of the inflammatory myocardial abnormalities and no residual fibrosis.
This case highlights the value of early multimodality cardiac imaging, etiologic diagnosis, and coordinated cardio-hematologic management in recognizing potentially reversible eosinophilic myocardial injury and limiting progression to irreversible cardiac sequelae.
Downloads
Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC guidelines for the management of myocarditis and pericarditis. Eur Heart J 2025;46:3952-4041. DOI: https://doi.org/10.1093/eurheartj/ehaf192
Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis. J Am Coll Cardiol 2017;70:2363-75. DOI: https://doi.org/10.1016/j.jacc.2017.09.023
Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol 2024;99:946-68. DOI: https://doi.org/10.1002/ajh.27287
Venkataramany BS, Brar A, Ahart Z, et al. Eosinophilic myocarditis associated with chronic eosinophilic leukemia. JACC Case Rep 2025;30:104805. DOI: https://doi.org/10.1016/j.jaccas.2025.104805
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405. DOI: https://doi.org/10.1182/blood-2016-03-643544
Legrand F, Renneville A, MacIntyre E, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine 2013;92:e1-9. DOI: https://doi.org/10.1097/MD.0b013e3182a71eba
Piccirillo F, Mastroberardino S, Nafisio V, et al. Eosinophilic myocarditis: from bench to bedside. Biomedicines 2024;12:656. DOI: https://doi.org/10.3390/biomedicines12030656
Kawano S, Kato J, Kawano N, et al. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern Med 2011;50:975-81. DOI: https://doi.org/10.2169/internalmedicine.50.4079
Aggarwal HK, Jain D, Kaverappa V, et al. Idiopathic hypereosinophilic syndrome presenting as severe Loeffler’s endocarditis. Arq Bras Cardiol 2013;100:e43-6. DOI: https://doi.org/10.5935/abc.20130081
Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood 2008;112:1005-12. DOI: https://doi.org/10.1182/blood-2008-02-140665
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.